Rofecoxib, Merck, and the FDA [1] (multiple letters)

New England Journal of Medicine

Volumn 351, Issue 27, 2004, Pages 2875-2878

  Kim, Peter S ^a   Reicin, Alise S ^a   Villalba, Lourdes ^b   Witter, James ^b   Wolfe, M Michael ^c   Topol, Eric J ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE; ANTITHROMBOCYTIC AGENT; CELECOXIB; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLORECTAL DISEASE; DRUG EFFECT; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; SIDE EFFECT; STOMACH POLYP; STROKE; THROMBOCYTE AGGREGATION; CHEMICALLY INDUCED DISORDER; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HISTORY; INTESTINE PERFORATION; NOTE; POSTMARKETING SURVEILLANCE; UNITED STATES; DRUG INTERACTION; GASTROINTESTINAL DISEASE; CONTROLLED CLINICAL TRIAL; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; HISTORY, 21ST CENTURY; HUMANS; INTESTINAL PERFORATION; LACTONES; PRODUCT SURVEILLANCE, POSTMARKETING; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; ASPIRIN; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HISTORY, 20TH CENTURY; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; SULFONAMIDES; RANDOMIZED CONTROLLED TRIALS;

EID: 13744259440     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200412303512719     Document Type: Letter

References (0)